
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp is a biopharmaceutical company poised for growth in the pulmonary hypertension market, particularly through its innovative product YUTREPIA, which is anticipated to capture a share of an expanding market valued at $3B-$4B. The company’s commitment to developing its sustained-release liposomal treprostinil formulation, L606, is expected to differentiate it from existing options by enhancing drug exposure and tolerability for both PAH and PH-ILD patients. With approximately $204 million in cash as of September 30, 2024, Liquidia is well-positioned to support the upcoming launch of YUTREPIA, bolstering its financial outlook and strategic initiatives.
Bears say
Liquidia Corp's recent financial performance has shown significant challenges, highlighted by a net loss of $23.2 million, or $0.30 per share for the third quarter of 2024. The company's stock performance was negatively impacted by a delay in FDA approval for its product, YUTREPIA, which faced heightened competition from established players, such as United Therapeutics and Actelion, further complicating commercialization efforts. Additionally, key risks remain, including the possibility of failing to secure capital for future operations and not achieving revenue projections due to market constraints and competitive pressures.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares